{ "items": [ "\n\n
\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n5 May 2020
\n \n \n \nDuncan Richards, Climax Professor of Clinical Therapeutics and Director of the Oxford Clinical Trials Research Unit (OCTRU) is interviewed about clinical trials and the challenges of running them in a pandemic.
\n \n\n \n \n\n \n\n \n \n \n \n Clinical Trials\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n1 May 2020
\n \n \n \nThe SEBCOV study aims to produce evidence to inform public health measures such as communications, quarantine, self-isolation, social distancing, and travel restrictions for the COVID-19 pandemic. This study is run in four countries: UK, Thailand, Italy and Malaysia.
\n \n\n \n \n\n \n\n \n \n \n \n Awards and Appointments\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n30 April 2020
\n \n \n \nTwo different teams from the Medical Sciences Division have received a share of $14 million in funding from the Chan Zuckerberg Initiative as one of 29 projects that will explore emerging ideas regarding the role of inflammation in disease.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n30 April 2020
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Staff and student stories\n \n \n\n \n\n\n
\n \n\n \n30 April 2020
\n \n \n \nUsing simulated scenarios to train front-line staff in the COVID-19 response
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n30 April 2020
\n \n \n \nThe results of a placebo-controlled trial of remdesivir in COVID-19 patients have been published in the Lancet.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Innovation\n \n \n\n \n\n\n
\n \n\n \n30 April 2020
\n \n \n \nThe University of Oxford has today announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the University.
\n \n\n \n \n\n \n\n \n \n \n \n Awards and Appointments\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n29 April 2020
\n \n \n \nSix Oxford University academics, including three from the Medical Sciences Division, have been elected to the prestigious Fellowship of the Royal Society.
\n \n\n \n \n\n \n\n \n \n \n \n Awards and Appointments\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n29 April 2020
\n \n \n \nProfessor Kia Nobre (Department of Experimental Psychology) and Professor Fiona Powrie (Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences) are two of 120 new members and 26 new international members newly elected to the National Academy of Sciences in recognition of their distinguished and continuing achievements in original research.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n28 April 2020
\n \n \n \nBlog by Rima Shretta in the Centre for Tropical Medicine & Global Health (Nuffield Department of Medicine). \r\n\r\nAs the COVID-19 pandemic continues its path to LMICs, its impact is likely to be even more devastating, potentially reversing recent gains made in the management of other communicable diseases. Of particular concern is the impact of the COVID-19 pandemic on malaria. COVID-19 has been slow to arrive and spread across Africa; nevertheless, there are many reasons to be concerned about malaria within the current context of the COVID-19 pandemic.
\n \n\n \n \n\n \n\n \n \n \n \n Clinical Trials\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n27 April 2020
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n24 April 2020
\n \n \n \nResearchers at the Nuffield Department of Women\u2019s & Reproductive Health (NDWRH) are today starting a large, international study to evaluate the effects of Covid-19 in pregnancy.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n23 April 2020
\n \n \n \nDepartment of Physiology, Anatomy & Genetics (DPAG) scientists develop single-cell oxygen saturation imaging to study oxygen handling by red blood cells. New physiological techniques that measure the blood's oxygen saturation are particularly important in light of the current pandemic, as COVID-19 patients present an abnormally low concentration of oxygen in the blood.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n23 April 2020
\n \n \n \nResearchers from the University of Oxford are supporting a new government study to track coronavirus (COVID-19) in the general population.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n23 April 2020
\n \n \n \nThree more studies are being funded by the NIHR Oxford Biomedical Research Centre (BRC) to look at the way the body interacts with COVID19; these include assessing the safety of a new vaccine; the role that antibodies might play in plasma therapy; and blood biomarkers that determine adverse reactions in those that have been infected.\r\n\r\nThese three new studies follow three others announced on 6 April.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n22 April 2020
\n \n \n \nPeriods of lockdown during the COVID-19 situation likely to exacerbate problems with mood regulation, say experts at the University of Oxford
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n22 April 2020
\n \n \n \nCharvy Narain (Communications & Public Engagement Manager, Radcliffe Department of Medicine) follows up her February Oxford Science Blog with an update on the latest research taking place across the University of Oxford in the fight against COVID-19.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n20 April 2020
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n20 April 2020
\n \n \n \nA multi-site project, called \u2018What\u2019s the STORY?\u2019 has received funding from UK Research and Innovation (UKRI) to assess novel coronavirus infection rates in children and teenagers across the UK. Given the importance of this study to the national Covid-19 response it has been deemed a priority study for the National Institute for Health Research\u2019s (NIHR) Urgent Public Health Response.
\n \n\n \n \n\n \n\n \n \n \n \n Clinical Trials\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n20 April 2020
\n \n \n \nResearchers from Nuffield Department of Primary Care Health Sciences are now enrolling participants into PRINCIPLE, the first clinical trial of potential COVID-19 treatments to take place in GP practices.
\n \n\n \n \n